Cargando…

A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report

Solid pseudopapillary neoplasm (SPN) of the pancreas is rare relatively low-grade malignant neoplasm and metastasis rarely. Surgical resection is the primary treatment option for primary and metastatic lesions of SPN, and chemotherapy is often ineffective in non-operable SPNs. SPNs are characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Yu, Zhang, Yunkun, Pan, Evenki, Yang, Peng, Xu, Lingling, Sun, Jinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650638/
https://www.ncbi.nlm.nih.gov/pubmed/36387184
http://dx.doi.org/10.3389/fonc.2022.1022290
_version_ 1784828065841414144
author Shang, Yu
Zhang, Yunkun
Pan, Evenki
Yang, Peng
Xu, Lingling
Sun, Jinghua
author_facet Shang, Yu
Zhang, Yunkun
Pan, Evenki
Yang, Peng
Xu, Lingling
Sun, Jinghua
author_sort Shang, Yu
collection PubMed
description Solid pseudopapillary neoplasm (SPN) of the pancreas is rare relatively low-grade malignant neoplasm and metastasis rarely. Surgical resection is the primary treatment option for primary and metastatic lesions of SPN, and chemotherapy is often ineffective in non-operable SPNs. SPNs are characterized by the presence of somatic CTNNB1 exon 3 mutations, leading to the activation of Wnt/β-catenin/Cox-2 signal pathway. Here, we firstly report that a refractory liver metastatic pancreatic SPN patient after the failure of multi-line chemotherapies benefited from the Cox-2 selective inhibitor (Celecoxib) based on CTNNB1 D32V mutation detected by next-generation sequencing (NGS), achieving a more than 22-month progression-free survival without any adverse events. Our case provides a potential treatment option for liver metastatic SPN patients with CTNNB1 mutations and highlights the application of NGS for the better treatment decision making.
format Online
Article
Text
id pubmed-9650638
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96506382022-11-15 A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report Shang, Yu Zhang, Yunkun Pan, Evenki Yang, Peng Xu, Lingling Sun, Jinghua Front Oncol Oncology Solid pseudopapillary neoplasm (SPN) of the pancreas is rare relatively low-grade malignant neoplasm and metastasis rarely. Surgical resection is the primary treatment option for primary and metastatic lesions of SPN, and chemotherapy is often ineffective in non-operable SPNs. SPNs are characterized by the presence of somatic CTNNB1 exon 3 mutations, leading to the activation of Wnt/β-catenin/Cox-2 signal pathway. Here, we firstly report that a refractory liver metastatic pancreatic SPN patient after the failure of multi-line chemotherapies benefited from the Cox-2 selective inhibitor (Celecoxib) based on CTNNB1 D32V mutation detected by next-generation sequencing (NGS), achieving a more than 22-month progression-free survival without any adverse events. Our case provides a potential treatment option for liver metastatic SPN patients with CTNNB1 mutations and highlights the application of NGS for the better treatment decision making. Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9650638/ /pubmed/36387184 http://dx.doi.org/10.3389/fonc.2022.1022290 Text en Copyright © 2022 Shang, Zhang, Pan, Yang, Xu and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Shang, Yu
Zhang, Yunkun
Pan, Evenki
Yang, Peng
Xu, Lingling
Sun, Jinghua
A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report
title A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report
title_full A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report
title_fullStr A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report
title_full_unstemmed A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report
title_short A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report
title_sort refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored ctnnb1 mutation showed good response to celecoxib: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650638/
https://www.ncbi.nlm.nih.gov/pubmed/36387184
http://dx.doi.org/10.3389/fonc.2022.1022290
work_keys_str_mv AT shangyu arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT zhangyunkun arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT panevenki arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT yangpeng arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT xulingling arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT sunjinghua arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT shangyu refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT zhangyunkun refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT panevenki refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT yangpeng refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT xulingling refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport
AT sunjinghua refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport